	US 12,440,554 B2
	Vaccination using herpesvirus genomes in nucleic acid form
Dennis Hartigan-O'Connor, Davis, CA (US); Peter Barry, Davis, CA (US); Jesse Deere, Davis, CA (US); and Joseph Dutra, Davis, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Oct. 26, 2021, as Appl. No. 17/510,969.
Application 17/510,969 is a continuation of application No. PCT/US2020/031117, filed on May 1, 2020.
Claims priority of provisional application 62/842,419, filed on May 2, 2019.
Prior Publication US 2022/0105173 A1, Apr. 7, 2022
Int. Cl. A61K 39/245 (2006.01); A61K 39/00 (2006.01); C12N 7/00 (2006.01)

CPC A61K 39/245 (2013.01) [A61K 39/001186 (2018.08); C12N 7/00 (2013.01); C12N 2710/16034 (2013.01); C12N 2710/16043 (2013.01); C12N 2710/16045 (2013.01)]

38 Claims

1. A recombinant polynucleotide comprising:

(a) a Cytomegalovirus (CMV) genome;

(b) a sequence comprising a bacterial artificial chromosome (BAC) origin of replication; and

(c) two terminase complex recognition loci (TCRL) that flank the sequence comprising the BAC origin of replication, where each TCRL comprises two terminal repeats each comprising Pac1 and Pac2 sites;

wherein:

the CMV genome is separated from the sequence comprising the BAC origin of replication by the two TCRLs; and

the polynucleotide is circular.